Dr. Kai Liu is a seasoned scientist specializing in advanced drug delivery systems, with over six years of experience at AstraZeneca. Currently, Kai serves as an Associate Principal Scientist in Advanced Drug Delivery within the Pharmaceutical Sciences function, where he leads initiatives in developing high-throughput formulations and bioscience validations for lipid nanoparticle (LNP) delivery. His work significantly contributes to pioneering therapeutic genomic editing projects. During his industrial postdoctoral period at AstraZeneca, Kai further honed his expertise in nanoparticle technologies. He developed a world-leading high-throughput assay workflow for lipid nanoparticle biomolecular corona isolation and characterization, which was instrumental in supporting multiple therapeutic gene editing projects. Kai's academic journey began with a PhD at the Centre for BioNano Interactions, University College Dublin. His research focused on the cellular perturbations introduced by nanomaterials using cutting-edge omics techniques, contributing valuable insights into the mechanism of action for intestinal permeation enhancers in oral drug delivery. Beyond his research contributions, Kai Liu is a passionate advocate for the industry career path. He is eager to promote industry careers for young, emerging scientists, providing guidance and sharing his insights to help them navigate and succeed in the dynamic field of pharmaceutical sciences.
